LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40684778无 PMCID | 2025-Jul-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial).Circ JPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40159243无 PMCID | 2025-Jul-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40513285无 PMCID | 2025-Jul-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40513287无 PMCID | 2025-Jul-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40561681无 PMCID | 2025-Jul-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.Eur J Cancer | PMID 40580808PMC12687737 | 2025-Jul-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40454632无 PMCID | 2025-Jul-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40454646无 PMCID | 2025-Jul-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III clinical trial to assess the efficacy and safety of Yuping Tongqiao tablets in the treatment of persistent allergic rhinitis.J EthnopharmacolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40473149无 PMCID | 2025-Jul-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40548694无 PMCID | 2025-Jul-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ivermectin to Control Malaria - A Cluster-Randomized Trial.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40700688无 PMCID | 2025-Jul-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.Blood Adv | PMID 40305657PMC12274666 | 2025-Jul-22 | 0.95 | This is a subgroup analysis of a Phase III randomized trial, not the primary overall result. The abstract explicitly states it is an 'update' exploring the impact 'in patients aged ≥70 years enrolled in BMT CTN 1703.' While the underlying trial is eligible, this specific report is a subgroup analysis, which is excluded by the criteria. | 已完成 |
| Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40392667无 PMCID | 2025-Jul-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial.Lipids Health Dis已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:CONSORT/入组流程图;Fig. 3:AI 判定为 flow diagram;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。 | PMID 40696391PMC12281852 | 2025-Jul-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.Nat Commun | PMID 40691143PMC12280041 | 2025-Jul-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40446184无 PMCID | 2025-Jul-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40448572无 PMCID | 2025-Jul-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.Clin Infect Dis已检查 3 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other。 | PMID 39960062PMC12272848 | 2025-Jul-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40454643无 PMCID | 2025-Jul-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.N Engl J Med | PMID 40513032PMC13186568 | 2025-Jul-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40673584无 PMCID | 2025-Jul-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency.J Clin Endocrinol Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 39607675PMC12261095 | 2025-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study.Gut Liver已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other。 | PMID 39949051PMC12261127 | 2025-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.Am J Hypertens已检查 3 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。 | PMID 40178088PMC12260155 | 2025-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial.Aesthet Surg J已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 1 张未列出。 | PMID 40242960PMC12260373 | 2025-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study.J Neurol SciPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40450840无 PMCID | 2025-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).Cancer入排复审未纳入:The record reports results from a randomized, Phase 3b/Phase II study, but the primary endpoint is safety (incidence of anaphylactic reactions), not a time-to-event efficacy endpoint (e.g., OS, PFS). There is no mention of Kaplan-Meier analysis, hazard ratios, or any key secondary time-to-event efficacy outcome. | PMID 40614118PMC12229271 | 2025-Jul-15 | 0.95 | The record reports results from a randomized, Phase 3b/Phase II study, but the primary endpoint is safety (incidence of anaphylactic reactions), not a time-to-event efficacy endpoint (e.g., OS, PFS). There is no mention of Kaplan-Meier analysis, hazard ratios, or any key secondary time-to-event efficacy outcome. | 无 KM 图 |
| Influence of different photobiomodulation protocols on the prevention of chemotherapy-induced dysgeusia in breast cancer patients treated with Doxorubicin-Cyclophosphamide: a phase III, randomized, triple-blinded non-inferiority clinical trial.Support Care CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40658227无 PMCID | 2025-Jul-14 | 0.85 | This is a Phase III randomized trial in human breast cancer patients, but it evaluates photobiomodulation for preventing chemotherapy-induced dysgeusia (taste dysfunction) and quality-of-life outcomes. It does not report survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes required for Kaplan-Meier digitization. | 无 KM 图 |
| Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch.World J Gastroenterol已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 40678712PMC12264858 | 2025-Jul-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40570869无 PMCID | 2025-Jul-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection.J Infect Dis已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 2 张未列出。 | PMID 39172632PMC12247815 | 2025-Jul-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America.J Infect Dis已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。 | PMID 40100744PMC12247829 | 2025-Jul-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915.J Immunother Cancer | PMID 40645660PMC12248205 | 2025-Jul-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Relationship Between Third-Trimester Low Maternal Blood Pressure and Small-for-Gestational-Age Birth Weight in Pregnant Individuals With Mild Chronic Hypertension.Obstet Gynecol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40638923PMC12252258 | 2025-Jul-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图。 | PMID 40311141PMC12225732 | 2025-Jul-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40378359无 PMCID | 2025-Jul-10 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| As-Needed Albuterol-Budesonide in Mild Asthma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40388330无 PMCID | 2025-Jul-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intravenous Tenecteplase before Thrombectomy in Stroke.N Engl J Med入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40396577无 PMCID | 2025-Jul-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.J Clin Oncol | PMID 40408605PMC12225728 | 2025-Jul-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40454641无 PMCID | 2025-Jul-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Hypertensive disorders of pregnancy and perinatal outcomes: two prospective cohort studies of nulliparous women in India and Tanzania.BMJ Glob HealthPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40639854PMC12258372 | 2025-Jul-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study.BMC Ophthalmol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40634898PMC12243367 | 2025-Jul-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Estimated Theoretical Benefit of Aggressive LDL Lowering in Patients With Symptomatic Intracranial Atherosclerosis.NeurologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40446174无 PMCID | 2025-Jul-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Association and predictive value of the triglyceride glucose-weight adjusted waist index for cardiovascular outcomes in patients with type 2 diabetes.Sci Rep | PMID 40628839PMC12238582 | 2025-Jul-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial.Curr Oncol | PMID 40710200PMC12293772 | 2025-Jul-07 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40543520无 PMCID | 2025-Jul-05 | 0.95 | The study is a well-designed Phase 3 randomized trial in oncology with a time-to-event primary endpoint and reports original results. However, the intervention (radioiodine ablation) is a radiopharmaceutical/radiologic procedure, not a traditional drug intervention (e.g., chemotherapy, targeted therapy, immunotherapy). Per the adjudication criteria, a drug-containing intervention is required, and this study does not meet that specific criterion. | 无 KM 图 |
| Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40544857无 PMCID | 2025-Jul-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.Oncologist已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:生活质量量表图;Figure 3:生活质量量表图。 | PMID 39673779PMC12311279 | 2025-Jul-04 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.Oncologist已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 40613752PMC12231594 | 2025-Jul-04 | 0.85 | The study is a Phase III randomized trial with drug intervention and primary results, but the primary/key secondary efficacy endpoints reported (ORR, DOR) are not time-to-event endpoints as defined by the criteria. No Kaplan-Meier or HR analysis is indicated in the abstract. | 无 KM 图 |
| Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.Oncologist疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图。 | PMID 40622010PMC12230790 | 2025-Jul-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |